Outcomes and Risk Factors in Patients with Hematologic Malignancies Following Late-Stage SARS-CoV-2 Infection
Lina Wang,Jiang Liu,Yafang Guo,Meiling Zhao,Bozheng Zhang,Junyan Zhang,Ruijuan Zhang
DOI: https://doi.org/10.2147/jmdh.s491098
2024-12-09
Journal of Multidisciplinary Healthcare
Abstract:Lina Wang, 1 Jiang Liu, 1 Yafang Guo, 1 Meiling Zhao, 1 Bozheng Zhang, 2 Junyan Zhang, 3 Ruijuan Zhang 1 1 Department of Hematology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, People's Republic of China; 2 Department of Pediatrics, College of Arts and Sciences, Emory University, Atlanta, GA, USA; 3 Department of Clinical Epidemiology and Evidence-Based Medicine, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, People's Republic of China Correspondence: Ruijuan Zhang; Junyan Zhang, Email ; Purpose: To investigate the outcomes and risk factors for patients with hematologic malignancies (HM) following late-stage SARS-CoV-2 infection. Background: Patients with HM such as lymphoproliferative malignancies (including acute lymphoblastic leukemia and multiple myeloma) and myeloproliferative malignancies (including acute myeloid leukemia, myeloproliferative neoplasm, and myelodysplastic syndrome) are at increased risk of severe illness and high mortality from COVID-19. This study examines the impact of SARS-CoV-2 infection severity on HM prognosis during the late phase of COVID-19, using data from 203 patients at Shanxi Bethune Hospital. Methods: This is a retrospective cohort study. Data was collected from hospitalized HM patients at a single center from December 1, 2023, to December 31, 2023. The primary outcome was overall survival (OS). Multivariable Cox regression was used to identify risk factors. Results: This analysis includes data from 203 hospitalized patients with HM aged 36 to 67 years (median, 58 years). SARS-CoV-2 infection was observed in 42.86% (87/203) of the patients, among whom severe/critical cases accounted for 14.29% (29/203). Multivariable Cox regression shows active disease (hazard ratio [HR] 2.16, 95% confidence interval [CI] 1.00– 4.64, p = 0.049), hematopoietic stem cell transplantation (HSCT) (HR 4.06, 95% CI 1.02– 16.12, p = 0.047), and targeted therapy (HR 2.60, 95% CI 1.23– 5.50, p = 0.012) were associated with a higher incidence of progression. In contrast, individuals whose platelets count ≥ 50× 10 9 /L at baseline (HR = 0.36, 95% CI 0.17– 0.78, p = 0.009) and ferritin levels less than 500 μg/L (HR = 0.54, 95% CI 0.34– 0.86, p = 0.010) were associated with a lower incidence of progression. Active status (HR 7.06, 95% CI 2.10– 23.76, p = 0.002), HSCT (HR 7.17, 95% CI 1.10– 46.63, p = 0.039), and severe/critical SARS-CoV-2 infection in HM patients (HR 11.98, 95% CI 2.57– 55.82, p = 0.002) were associated with higher incidences of all cause of mortality. While a higher platelet level (≥ 50× 10 9 /L) was linked to a lower mortality (HR 0.16, 95% CI 0.05– 0.49, p = 0.002). Conclusion: In the late stage of the COVID-19 pandemic, active disease status, recent HSCT, and severe/critical SARS-CoV-2 infection significantly increased the risks of disease progression and mortality in HM patients. Higher baseline platelet counts were associated with improved outcomes. Keywords: late stage of COVID-19, hematologic malignancies, progression-free survival, overall survival In March 2020, the WHO declared COVID-19, a disease caused by SARS-CoV-2, to be a global pandemic. 1 After three years of the COVID-19 pandemic, understanding the late-stage effects of SARS-CoV-2 infection on patients with hematologic malignancies (HM) can help guide clinical management. In the early stages of SARS-CoV-2 infection, most studies suggest that patients with HM face an increased risk of developing severe cases of the illness, with mortality rates exceeding 30%. 2–4 Currently, we cannot predict which patients with HM are more likely to contract COVID-19. However, multivariate Cox regression analysis revealed that specific HM such as acute myeloid leukemia (AML), multiple myeloma (MM), and non-Hodgkin's lymphoma demonstrate a higher risk of mortality from COVID-19, with hazard ratios of 3.49, 2.48, and 2.19, respectively. 5–7 Anticancer treatments, essential for managing HM, can further complicate the course of COVID-19. Therapies such as anti-CD20 monoclonal antibody therapy, chimeric antigen receptor T-cell (CAR-T) therapy, and hematopoietic stem cell transplantation (HSCT) not only weaken the immune response but also extend the duration of viral shedding, potentially increasing the period of infectivity and the risk of severe COVID-19. 7 However, after the onset of the 2/3 wave of SARS-CoV-2 infections, along with the understanding of the novel coronavirus and the publicati -Abstract Truncated-
health care sciences & services